title: CD56 expression in normal immature granulocytes after allogeneic hematopoietic stem cell transplantation.
abstract: Bone marrow mononuclear cells from 93 patients with hematological malignancies after allogeneic hematopoietic stem cell transplantation (AHSCT) were analyzed using flow cytometry (FCM). The disease was acute myeloblastic leukemia (50 patients), acute lymphoblastic leukemia, and others. Conditioning was myeloablative (80 patients) or reduced intensity. The stem cell source was bone marrow (75 patients), peripheral blood stem cells, or cord blood. After AHSCT, granulocyte colony-stimulating factor was given to all patients. All patients showed engraftment of the donor cells. FCM was conducted on a median of 22 days after AHSCT. The gate was set around a granulocytic region consisting of immature granulocytes. The positivity rates of CD13, CD14, CD15, CD33, CD34, CD56, and HLA-DR in the cells were 59.9 ± 27.4%, 5.8 ± 8.8%, 98.3 ± 1.9%, 92.3 ± 12.4%, 2.6 ± 5.8%, 24.3 ± 16.7%, and 9.1 ± 6.6%, respectively. The greatest value of CD56 positivity was 73.1%. On the basis of CD56 expression, cases of more than 24% CD56 positivity were assigned to the CD56-high group (39 patients), while the rest were assigned to the CD56-low/negative group. There were no significant differences between the two groups in terms of disease status, sex, donor, hematopoietic stem cells, days of FCM analysis, or peripheral blood cell counts around the days of performing FCM. These results indicate that CD56 can be expressed in normal immature granulocytes at a variety of expression levels in regenerative bone marrow. Attention should be paid when evaluating aberrant antigen expression of CD56 in granulocytes.
authors.affiliation: Division of Cell Therapy, Jichi Medical University Hospital, Shimotsuke.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Muroi
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Fujiwara
authors.forename: Raine
authors.initials: R
authors.lastname: Tatara
authors.forename: Miyuki
authors.initials: M
authors.lastname: Sugimoto
authors.forename: Chihiro
authors.initials: C
authors.lastname: Yamamoto
authors.forename: Eisuke
authors.initials: E
authors.lastname: Uehara
authors.forename: Akiko
authors.initials: A
authors.lastname: Meguro
authors.forename: Kaoru
authors.initials: K
authors.lastname: Hatano
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Okazuka
authors.forename: Iekuni
authors.initials: I
authors.lastname: Oh
authors.forename: Ken
authors.initials: K
authors.lastname: Ohmine
authors.forename: Takahiro
authors.initials: T
authors.lastname: Suzuki
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
authors.forename: Tadashi
authors.initials: T
authors.lastname: Nagai
authors.forename: Keiya
authors.initials: K
authors.lastname: Ozawa
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000954:Antigens, Surface / Q000378:metabolism; D019002:CD56 Antigen / Q000235:genetics / Q000378:metabolism*; D005260:Female; D015870:Gene Expression; D006098:Granulocytes / Q000166:cytology* / Q000378:metabolism*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016130:Immunophenotyping; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D000954:Antigens, Surface; D019002:CD56 Antigen